Literature DB >> 8524826

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

T C Wu1, F G Guarnieri, K F Staveley-O'Carroll, R P Viscidi, H I Levitsky, L Hedrick, K R Cho, J T August, D M Pardoll.   

Abstract

The presentation of antigenic peptides by major histocompatibility complex (MHC) class II molecules to CD4+ T cells is critical to the function of the immune system. In this study, we have utilized the sorting signal of the lysosomal-associated membrane protein LAMP-1 to target a model antigen, human papillomavirus 16 E7 (HPV-16 E7), into the endosomal and lysosomal compartments. The LAMP-1 sorting signal reroutes the antigen into the MHC class II processing pathway, resulting in enhanced presentation to CD4+ cells in vitro. In vivo immunization experiments in mice demonstrated that vaccinia containing the chimeric E7/LAMP-1 gene generated greater E7-specific lymphoproliferative activity, antibody titers, and cytotoxic T-lymphocyte activities than vaccinia containing the wild-type HPV-16 E7 gene. These results suggest that specific targeting of an antigen to the endosomal and lysosomal compartments enhances MHC class II presentation and vaccine potency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8524826      PMCID: PMC40464          DOI: 10.1073/pnas.92.25.11671

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Diverse migratory pathways in the developing cerebral cortex.

Authors:  N A O'Rourke; M E Dailey; S J Smith; S K McConnell
Journal:  Science       Date:  1992-10-09       Impact factor: 47.728

Review 2.  Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function.

Authors:  J R Bennink; J W Yewdell
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

3.  Different regulation of class I gene expression in the adult mouse and during development.

Authors:  J M Drezen; P Nouvel; C Babinet; D Morello
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

4.  Human papillomavirus type 16 E7 protein expressed in Escherichia coli and monkey COS-1 cells: immunofluorescence detection of the nuclear E7 protein.

Authors:  H Sato; S Watanabe; A Furuno; K Yoshiike
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

Review 5.  Do cortical areas emerge from a protocortex?

Authors:  D D O'Leary
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

6.  A self-renewing multipotential stem cell in embryonic rat cerebral cortex.

Authors:  A A Davis; S Temple
Journal:  Nature       Date:  1994-11-17       Impact factor: 49.962

Review 7.  Immunology of the human papilloma virus in relation to cancer.

Authors:  T C Wu
Journal:  Curr Opin Immunol       Date:  1994-10       Impact factor: 7.486

8.  Targeting of a lysosomal membrane protein: a tyrosine-containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is necessary and sufficient for targeting to lysosomes.

Authors:  C Peters; M Braun; B Weber; M Wendland; B Schmidt; R Pohlmann; A Waheed; K von Figura
Journal:  EMBO J       Date:  1990-11       Impact factor: 11.598

9.  Tangential migration of neurons in the developing cerebral cortex.

Authors:  N A O'Rourke; D P Sullivan; C E Kaznowski; A A Jacobs; S K McConnell
Journal:  Development       Date:  1995-07       Impact factor: 6.868

10.  Identification of two lysosomal membrane glycoproteins.

Authors:  J W Chen; T L Murphy; M C Willingham; I Pastan; J T August
Journal:  J Cell Biol       Date:  1985-07       Impact factor: 10.539

View more
  92 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

2.  Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Authors:  Dannie Bernard; Michael S Ventresca; Laura A Marshall; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 3.  Presentation of cytosolic antigens via MHC class II molecules.

Authors:  Delu Zhou; Janice S Blum
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

5.  Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef.

Authors:  Daniel G Kavanagh; Daniel E Kaufmann; Sherzana Sunderji; Nicole Frahm; Sylvie Le Gall; David Boczkowski; Eric S Rosenberg; David R Stone; Mary N Johnston; Bradford S Wagner; Mohammad T Zaman; Christian Brander; Eli Gilboa; Bruce D Walker; Nina Bhardwaj
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

Review 6.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

7.  DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency.

Authors:  Chien-Fu Hung; Ya-Chea Tsai; Liangmei He; T-C Wu
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

Review 8.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

Review 9.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.